harrismartin.comSEP 221 min read$MCK

Claims Against Sagent Pharma, McKesson Proceed in Contaminated Corticosteroid Action

A federal judge in West Virginia refused to dismiss claims of manufacturing defect, negligence, and breach of warranty against Sagent Pharmaceuticals and McKesson Medical-Surgical. The lawsuit alleges a contaminated corticosteroid injection led to a woman's toe amputation. The judge dismissed the failure-to-warn claim, citing federal law preemption.

Original reporting

harrismartin.com

Published Sep 22, 2026, 10:15 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Sep 22, 2026, 10:30 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

Claims Against Sagent Pharma, McKesson Proceed in Contaminated Corticosteroid Action — source image — Source · harrismartin.com

Decision brief

The 30-second read

$MCKBearishLow

Why it matters

The legal claims could result in financial penalties, increased compliance costs, and reputational damage for the companies involved.

Market read

Legal exposure may affect stock valuations of Sagent and McKesson, prompting traders to monitor developments.

What to watch

Potential insurance coverage and prior safety protocols could mitigate losses.

Relevance 5/10Novelty 5/10Timing: Sept 21 order

Background

Contaminated corticosteroid injections have led to lawsuits and recalls in the past, raising scrutiny on drug manufacturing and distribution practices.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$MCKBearishMedium confidence

Context

McKesson Medical-Surgical faces the same lawsuit over the contaminated corticosteroid injection.

Expected impact

downward pressure

Evidence & confidence

As a distributor, McKesson could face damages and reputational risk.

Market effects

Sector

Highlights ongoing risks in pharmaceutical manufacturing and medical-surgical distribution.

Regional

May affect US pharma and medical supply stocks.

Global

Limited to companies directly involved.

Counterpoint

What could challenge this read

The lawsuit may be settled quickly with minimal financial impact.

Key entities

Company
Sagent Pharmaceuticals Inc.
Pharmaceutical manufacturer facing lawsuit.
Company
McKesson Medical-Surgical Inc.
Distributor implicated in the same lawsuit.
Person
Judge Irene Berger
U.S. District Judge handling the case.

Read at source ← All news

SEP 15

$MCKMed

Does Raised EPS Guidance Change The Bull Case For McKesson Stock (MCK)?

McKesson (MCK) raised its full-year EPS guidance to 13-15% (15-17% excluding prior-year items) and plans to rebrand its Medical-Surgical unit as Wellverse, targeting an IPO in 2H 2027. The company also aims to acquire Precision Medicine Group to expand oncology and biopharma services. Management highlights core operations are tracking ahead, but structural pressures on drug pricing and high leverage remain risks. McKesson projects $502.2B revenue and $6.3B earnings by 2029, implying 6.9% yearly

simplywall.st3 min

SEP 14

$MCKHigh

McKesson Raises Outlook, Eyes Oncology Growth With Precision Medicine Deal

McKesson (MCK) raised its outlook, citing growth in its Oncology & Multispecialty segment, which saw 33% revenue growth and 41% adjusted operating profit growth in Q1. The company also announced a deal for Precision Medicine Group, expected to be strategically and financially accretive. McKesson's RxTS segment grew 9% in revenue and 13% in adjusted operating profit, with GLP-1-related business accounting for 11% of its revenue. The company plans to invest more in growth, automation, and technolo

yahoo.com2 min

SEP 8

$MCKMed

McKesson Eyes $2.25B Precision Medicine Deal as Oncology Growth Accelerates

McKesson (MCK) plans a $2.25B precision medicine acquisition, expecting strategic alignment and value creation. Q1 revenue grew 5% in North American Pharmaceutical Distribution and 33% in Oncology. The company aims to return $5B to shareholders this year, including $2.5B in share repurchases and a 15% dividend increase. McKesson also expects to separate its Medical-Surgical business, rebranded as Wellverse, by late 2024.

yahoo.com6 min

SEP 7

$CAHMedAI 8/10

4 companies on verge of settling US opioid lawsuits

AmerisourceBergen, Cardinal Health, McKesson, and Johnson & Johnson are nearing a $26B settlement for opioid lawsuits. New York reached a separate $1B deal with the distributors. Johnson & Johnson will contribute up to $5B nationally. Trials continue elsewhere.

pressdemocrat.com3 min

SEP 6

$MCKMedAI 8/10

McKesson Bets $2.25 Billion More on Oncology With Precision Medicine Buy

McKesson (NYSE:MCK) to acquire Precision Medicine Group for $2.25B, expanding its oncology and specialty care business. The deal aims to enhance clinical research and commercialization services, with Precision Medicine joining McKesson's Oncology & Multispecialty segment. McKesson has been divesting non-core assets to fund such investments, and the Oncology segment saw 33% revenue growth in Q1 2026. However, the deal's timeline and integration risks remain uncertain.

yahoo.com3 min

SEP 5

$MCKHighAI 8/10

McKesson Stock: Is MCK Outperforming the Healthcare Sector?

McKesson (MCK), a $107.4B healthcare distributor, has outperformed the sector, rising 24.6% in 3 months and 33.4% in 52 weeks. Q1 2027 revenue hit $105.4B, up 7.7% YoY, with adjusted EPS of $9.93. The company raised full-year EPS guidance to $44.60. Analysts rate MCK a 'Strong Buy' with a $984.29 price target.